Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05088421




Registration number
NCT05088421
Ethics application status
Date submitted
9/09/2021
Date registered
21/10/2021
Date last updated
6/07/2023

Titles & IDs
Public title
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Secondary ID [1] 0 0
C001-2020-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Infectious Diseases 0 0
Bacterial Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BWC0977
Treatment: Drugs - Placebo

Experimental: BWC0977 - SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hours. Planned doses to be studied are 120, 240, 480, 720, and 1050mg.
MAD Cohorts: Subjects will receive multiple doses of 240mg TID 7 days, 350mg TID 7 days BWC0977 via IV infusion over 2 hours in the first 2 cohorts. The dose for the B3 cohort will be determined based on safety and tolerability data from the previous two cohorts Up to three dose groups will be studied.

Placebo Comparator: Placebo - Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hour.
MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hour for 10 consecutive days. Frequency of infusions will be determined based on safety, tolerability and PK data obtained for BWC0977 in SAD Cohorts.


Treatment: Drugs: BWC0977
SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.
MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.

Treatment: Drugs: Placebo
SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of treatment-emergent adverse events (TEAEs and serious adverse events (SAEs) overall and by intensity (Safety and tolerability).
Timepoint [1] 0 0
SAD: Up to 7 days; MAD: Up to 15 days.
Secondary outcome [1] 0 0
AUC[0-t] of BWC0977 following single dose administration
Timepoint [1] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [2] 0 0
AUC[0-inf]) of BWC0977 following single dose administration
Timepoint [2] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [3] 0 0
AUC[0-8], AUC[0-12], AUC[0-24]) of BWC0977 following single dose administration
Timepoint [3] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [4] 0 0
Cmax of BWC0977 following single dose administration
Timepoint [4] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [5] 0 0
Cmax of BWC0977 following repeat dose administration
Timepoint [5] 0 0
Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start
Secondary outcome [6] 0 0
Terminal half-life (T1/2)
Timepoint [6] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [7] 0 0
Systemic clearance (CL) following single dose administration
Timepoint [7] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [8] 0 0
Systemic clearance (CL) following repeat dose administration
Timepoint [8] 0 0
Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start
Secondary outcome [9] 0 0
Volume of distribution at steady state (Vdss) following single dose administration
Timepoint [9] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [10] 0 0
Mean residence time (MRT) following single dose administration
Timepoint [10] 0 0
Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start
Secondary outcome [11] 0 0
Pre-dose (trough) concentration (Ct) at the end of the dosing interval
Timepoint [11] 0 0
Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start
Secondary outcome [12] 0 0
Observed accumulation ratio following repeat dose administration
Timepoint [12] 0 0
Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start
Secondary outcome [13] 0 0
Volume of distribution at steady state following repeat dose administration
Timepoint [13] 0 0
Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start

Eligibility
Key inclusion criteria
Each subject must meet all of the following criteria to be eligible for study
participation:

1. Healthy male or female 18 to 55 years of age, inclusive, at time of consent.

2. Body mass index (BMI) = 19.0 and = 30.0 (kg/m2) and weight between 55.0 and 100.0 kg
(inclusive).

3. Medically healthy without clinically significant abnormalities at the screening visit
or Day -1, including:

1. No findings in Physical examination or vital signs (including temperature, heart
rate, respiratory rate, and blood pressure) that the Principal Investigator (PI)
determines would interfere with interpretation of study results.

2. Electrocardiograms (ECGs) without clinically significant abnormalities, including
a QT duration corrected for heart rate by Fridericia's formula (QTcF) interval
duration =450 msec (for males), and =470 msec (for females) obtained as an
average from the triplicate screening ECGs after at least 5 minutes in a supine
quiet-rest position.

3. Clinically significant abnormalities in the screening clinical laboratory tests,
as determined by the Investigator. Repeat testing could be performed at the
Investigator's discretion.

4. Willing
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Volunteers who meet any of the following criteria will be excluded from the study:

1. Women who are pregnant and/or nursing.

2. History or presence of significant cardiovascular (including QT prolongation,
clinically significant hypokalemia, or other proarrhythmic conditions), pulmonary,
hepatic, renal, hematological, gastrointestinal, endocrine (including glucose
intolerance, diabetes mellitus), immunologic (including asthma or seasonal allergies
[that require intermittent use of steroids or other medication]), musculoskeletal
(including tendinopathy), dermatologic, or neurological disease (including seizure
disorders, psychiatric disorders), including any acute illness or surgery within the
past 3 months determined by the PI to be clinically relevant.

3. A serum creatinine value on Day -1 (check-in) that increased by more than 0.2 mg/dL
(or 15.25 µmol/L) from the Screening value.

4. History of photosensitivity to quinolones.

5. History of known or suspected Clostridium difficile infection.

6. Any condition that necessitated hospitalisation within the 3 months prior to Day -1 or
is likely to require so during the study.

7. Positive test for hepatitis B virus surface antigen (HBsAg), hepatitis C virus
antibody (anti-HCV antibodies), or human immunodeficiency virus antibody (antibodies
to HIV-1, HIV-2) or tuberculosis (TB) at screening.

8. Exposure to any prescription medications (small molecules, biologics including
vaccines) or, systemically administered OTC drugs, dietary supplements or herbal
remedies, within 30 days or 5 half-lives (if known), whichever is longer, prior to Day
-1. Discussion between the PI and the Sponsor Medical Monitor is encouraged regarding
prior use of any medications during the pre-dose period.

Note: An exception is made for hormonal contraceptives and a limited amount of
paracetamol (a maximum of 4 doses per day of 500-mg paracetamol, and no more than 3 g
per week) for the treatment of headache or any other pain.

9. Documented hypersensitivity reaction or anaphylaxis to any medication.

10. Smoker (including tobacco, e-cigarettes or marijuana) or nicotine user within 1 month
prior to participation in the study

11. Positive urine drug/alcohol testing at screening or check-in (Day -1), or history of
substance abuse or alcohol abuse (defined as greater than 2 standard drinks on average
each and every day, where one standard drink is defined as containing 10 g of alcohol
and is equivalent to 1 can or stubby of mid-strength beer, 30 ml nip spirits, or 100
ml wine) within the previous 5 years (may be repeated once per timepoint, at the
discretion of the PI, in the instance of a positive result).

12. Donation of blood or plasma within 30 days prior to randomization, or loss of whole
blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood
transfusion within 1 year of study enrollment.

13. Previous participation in this study or previous participation in another study within
5 half-lives (if known) of the agent, whichever is longer, of Day 1. Note: prior
participation at any time in non-invasive methodology trials in which no drugs were
given is acceptable.

14. Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos,
other citrus fruits, grapefruit hybrids or fruit juices containing such products from
7 days prior to the first dose of study medication.

15. Employee or family member of an employee of the Sponsor, CRU, or clinical research
organization at which the study will be conducted.

16. Unable to cooperate fully with the requirements of the study protocol, including the
schedule of assessments, or likely to be non-compliant with any study requirements.

17. Any disease or condition (medical or surgical) that, by the determination of the PI,
precludes the subject's participation in the study or would place the subject at risk
as a result of participation in the study.

Note: Volunteers should refrain from consumption of any foods containing poppy seeds within
48 hours (2 days) prior to screening and prior to Day -1 to avoid false positive drug
screen results

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/05/2023
Sample size
Target
Accrual to date
Final
44
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bugworks Research Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Avance Clinical Pty Ltd.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
single and multiple intravenous doses of BWC0977 when administered to healthy adult
volunteers.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05088421
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Angela Molga, MD
Address 0 0
CMAX Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05088421